Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Aug 7

PMID 34359742

Citations 19

Authors

Yohei Hisada

Nigel Mackman

Affiliations

Soon will be listed here.

Abstract

Tissue factor (TF) is a transmembrane glycoprotein that functions as a receptor for FVII/FVIIa and initiates the extrinsic coagulation pathway. Tumors and cancer cells express TF that can be released in the form of TF positive (TF+) extracellular vesicles (EVs). In this review, we summarize the studies of tumor TF and TF + EVs, and their association with activation of coagulation and survival in cancer patients. We also summarize the role of tumor-derived TF + EVs in venous thrombosis in mouse models. Levels of tumor TF and TF + EVs are associated with venous thromboembolism in pancreatic cancer patients. In addition, levels of EVTF activity are associated with disseminated intravascular coagulation in cancer patients. Furthermore, tumor-derived TF + EVs enhance venous thrombosis in mice. Tumor TF and TF + EVs are also associated with worse survival in cancer patients, particularly in pancreatic cancer patients. These studies indicate that EVTF activity could be used as a biomarker to identify pancreatic cancer patients at risk for venous thrombosis and cancer patients at risk for disseminated intravascular coagulation. EVTF activity may also be a useful prognostic biomarker in cancer patients.

Citing Articles

Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism.

Lami V, Nieri D, Pagnini M, Gattini M, Donati C, De Santis M Biomolecules. 2025; 15(1.

PMID: 39858477 PMC: 11762650. DOI: 10.3390/biom15010083.

Exploring Extracellular Vesicle Surface Protein Markers Produced by Glioblastoma Tumors: A Characterization Study Using In Vitro 3D Patient-Derived Cultures.

Franceschi S, Lessi F, Morelli M, Menicagli M, Aretini P, Gambacciani C Cancers (Basel). 2024; 16(22).

PMID: 39594703 PMC: 11592176. DOI: 10.3390/cancers16223748.

A novel risk stratification approach and molecular subgroup characterization based on coagulation related genes in colon adenocarcinoma.

Wu X, Zhu L, Sun X, Xia M, Zhao S, Zhang B Cancer Cell Int. 2024; 24(1):309.

PMID: 39252019 PMC: 11386116. DOI: 10.1186/s12935-024-03491-2.

Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour.

Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D Cancers (Basel). 2024; 16(13).

PMID: 39001418 PMC: 11240748. DOI: 10.3390/cancers16132356.

Special Issue "Genetic, Functional and Therapeutic Aspects of Procoagulant and Anticoagulant Factors".

Livnat T, Dardik R Int J Mol Sci. 2024; 25(11).

PMID: 38891929 PMC: 11172113. DOI: 10.3390/ijms25115741.

References

Thomas G, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C . Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost. 2015; 13(7):1310-9. PMC: 4496280. DOI: 10.1111/jth.13002. View

Sorensen H, Mellemkjaer L, Olsen J, Baron J . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-50. DOI: 10.1056/NEJM200012213432504. View

Mulder F, Horvath-Puho E, van Es N, van Laarhoven H, Pedersen L, Moik F . Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2020; 137(14):1959-1969. DOI: 10.1182/blood.2020007338. View

Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J . Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008; 87(6):451-7. DOI: 10.1007/s00277-008-0446-3. View

Manly D, Wang J, Glover S, Kasthuri R, Liebman H, Key N . Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2009; 125(6):511-2. PMC: 2878897. DOI: 10.1016/j.thromres.2009.09.019. View

Thaler J, Ay C, Mackman N, Bertina R, Kaider A, Marosi C . Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012; 10(7):1363-70. DOI: 10.1111/j.1538-7836.2012.04754.x. View

Akashi T, Furuya Y, Ohta S, Fuse H . Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology. 2003; 62(6):1078-82. DOI: 10.1016/s0090-4295(03)00768-4. View

Kasthuri R, Hisada Y, Ilich A, Key N, Mackman N . Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. Res Pract Thromb Haemost. 2020; 4(4):636-643. PMC: 7292676. DOI: 10.1002/rth2.12317. View

Hisada Y, Thalin C, Lundstrom S, Wallen H, Mackman N . Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res. 2018; 165:1-5. PMC: 5943147. DOI: 10.1016/j.thromres.2018.03.001. View

10.

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

11.

Diaz J, Obi A, Myers Jr D, Wrobleski S, Henke P, Mackman N . Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol. 2012; 32(3):556-62. PMC: 3292052. DOI: 10.1161/ATVBAHA.111.244608. View

12.

Hisada Y, Ay C, Auriemma A, Cooley B, Mackman N . Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost. 2017; 15(11):2208-2217. DOI: 10.1111/jth.13809. View

13.

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A . Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013; 43(3):277-85. DOI: 10.1111/eci.12042. View

14.

El-Sheikh A, Borgstrom P, Bhattacharjee G, Belting M, Edgington T . A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment. Cancer Res. 2005; 65(23):11109-17. DOI: 10.1158/0008-5472.CAN-05-2733. View

15.

Coumans F, Brisson A, Buzas E, Dignat-George F, Drees E, El-Andaloussi S . Methodological Guidelines to Study Extracellular Vesicles. Circ Res. 2017; 120(10):1632-1648. DOI: 10.1161/CIRCRESAHA.117.309417. View

16.

Stark K, Schubert I, Joshi U, Kilani B, Hoseinpour P, Thakur M . Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo. Arterioscler Thromb Vasc Biol. 2018; 38(4):772-786. DOI: 10.1161/ATVBAHA.117.310262. View

17.

Hu Z, Garen A . Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A. 2000; 97(16):9221-5. PMC: 16849. DOI: 10.1073/pnas.97.16.9221. View

18.

Yang S, Yang L, Wu Y, Zhang C, Wang S, Ma N . Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma. Ann Transl Med. 2020; 8(20):1307. PMC: 7661863. DOI: 10.21037/atm-20-6619. View

19.

Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L . Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem. 2009; 112(3):233-9. DOI: 10.1016/j.acthis.2008.11.024. View

20.

Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C . PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. Cancers (Basel). 2019; 11(8). PMC: 6721522. DOI: 10.3390/cancers11081141. View